FDA OKs Brentuximab Vedotin Combo in R/R Large B-Cell Lymphoma
Data from the ECHELON-3 trial support the approval of the brentuximab vedotin combo in relapsed/refractory B-cell lymphoma.
Findings from the double-blind phase 3 ECHELON-3 trial (NCT04404283) support the FDA's regulatory decision.
The FDA has approved brentuximab vedotin (Adcetris) plus lenalidomide (Revlimid) and rituximab (Rituxan) for patients with relapsed/refractory large B-cell lymphoma (LBCL), according to a news release from the agency.1
Specifically, the indication extends to those with diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL resulting from indolent lymphoma, or high-grade B-cell lymphoma (HGBL) following at least 2 prior lines of treatment who are ineligible to receive CAR T-cell therapy or autologous hematopoietic stem cell transplantation (auto-HSCT).
Supporting data for the approval came from the double-blind phase 3 ECHELON-3 trial (NCT04404283), in which investigators assessed brentuximab vedotin plus lenalidomide/rituximab vs placebo plus lenalidomide/rituximab among 230 adults with LBCL. Topline data showed a median overall survival (OS) of 13.8 months (95% CI, 10.3-18.8) in the brentuximab vedotin arm vs 8.5 months (95% CI, 5.4-11.7) in the placebo arm (HR, 0.63; 95% CI, 0.45-0.89; P = .0085). Additionally, the median progression-free survival (PFS) was 4.2 months (95% CI, 2.9-7.1) vs 2.6 months (95% CI, 1.4-3.1) in each respective arm (HR, 0.53; 95% CI, 0.38-0.73; P <.0001), and the objective response rate (ORR) was 64.3% (95% CI, 54.7%-73.1%) vs 41.5% (95% CI, 32.5%-51.0%).
Findings from the ECHELON-3 trial were previously published in the Journal of Clinical Oncology.2 Additional data showed a median duration of response (DOR) of 8.3 months (95% CI, 4.2-15.3) in the brentuximab vedotin group and 3.0 months (95% CI, 2.8-5.4) in the placebo group.
Regarding safety, treatment-emergent AEs (TEAEs) of any grade occurred in 97% of patients who received brentuximab vedotin vs 97% of patients in the placebo arm; TEAEs of grade 3 or higher occurred in 88% and 77%, respectively. The most common TEAEs of grade 3 or higher in each arm included neutropenia (43% vs 28%), thrombocytopenia (25% vs 19%), anemia (22% vs 21%), and pneumonia (11% vs 5%).
The trial’s primary end point was OS. Key secondary end points included PFS, ORR, complete response rate, DOR per Lugano classification, and AEs.
The agency approved brentuximab vedotin at a recommended dose of 1.2 mg/kg up to 120 mg in combination with lenalidomide and rituximab every 3 weeks until progressive disease or unacceptable toxicity.
References
- FDA approves brentuximab vedotin with lenalidomide and rituximab for relapsed or refractory large B-cell lymphoma. News release. FDA. February 11, 2025. Accessed February 12, 2025. https://tinyurl.com/4mhcnndc
- Bartlett NL, Hahn U, Kim W-S, et al. Brentuximab vedotin combination for relapsed diffuse large B-cell lymphoma. J Clin Oncol. Published online January 7, 2025. doi:10.1200/JCO-24-02242
Highlighting Insights From the Marginal Zone Lymphoma Workshop
Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.
Rare Primary ALK-Positive Anaplastic Large Cell Lymphoma of the Central Nervous System
Anaplastic large cell lymphoma is a rapidly growing and aggressive hematological malignancy. This case highlights the rarity of isolated intradural extramedullary manifestations in the pediatric population.
